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ABSTRACT
Steroidogenic Factor-1 (SF-1) is a nuclear receptor
that has a pivotal role in the development of adrenal
glands and gonads and in the control of steroid
hormone production, being also implicated in the
pathogenesis of adrenocortical tumors. We have
analyzed the mechanisms how SF-1 controls gene
expression in adrenocortical cells and showed that
it regulates different categories of genes according
to its dosage. Significant correlations exist between
the localization of SF-1-binding sites in chromatin
under different dosage conditions and dosage-
dependent regulation of gene expression. Our
study revealed unexpected functional interactions
between SF-1 and Neuron-Restrictive Silencer
Factor/RE1-Silencing Transcription Factor (NRSF/
REST), which was first characterized as a repressor
of neuronal gene expression in non-neuronal
tissues, in the regulation of gene expression in
steroidogenic cells. When overexpressed, SF-1
reshapes the repertoire of NRSF/REST—regulated
genes, relieving repression of key steroidogenic
genes. These data show that NRSF/REST has a
novel function in regulating gene expression in
steroidogenic cells and suggest that it may have a
broad role in regulating tissue-specific gene expres-
sion programs.
INTRODUCTION
Steroidogenic Factor-1 (SF-1/Ad4BP) is a transcription
factor belonging to the nuclear receptor superfamily
(NR5A1 in the nuclear receptor nomenclature) that was
first identified as a regulator of the expression of
steroidogenic P-450 enzymes in the adrenal cortex (1,2)
and functions as a global regulator of steroidogenic gene
expression [reviewed in (3)]. Furthermore, SF-1 has a
pivotal role in adrenogonadal development and differen-
tiation into the steroidogenic lineage: mice lacking Sf1
have no adrenal glands and gonads, while its
overexpression in the embryo induces formation of
ectopic adrenal tissue (4–6). Multiple factors regulate
SF-1 activity: association with positive and negative co-
factors, post-translational modifications, phospholipid
ligand availability, epigenetic regulations and gene
dosage [reviewed in (7)]. In particular, alterations of SF-
1 dosage, both in defect and in excess, produce relevant
pathological effects. Sf-1 +/ mice have hypoplastic
adrenals and gonads (8) and impaired compensatory
adrenal growth following unilateral adrenalectomy (9).
In humans, heterozygote NR5A1 mutations are mostly
associated with disorders of sex development (10), with
only a few cases also displaying adrenal insufficiency
(11). On the other side of the spectrum, SF-1 over-
expression increases adrenocortical cancer cell prolifer-
ation and induces adrenocortical tumor formation in
mice (12) and in humans is associated to adrenocortical
tumorigenesis both in children (13) and adults (14).
The aim of this work was to study how differences in
SF-1 dosage are connected to regulation of gene expres-
sion in adrenocortical cancer cells and to investigate the
mechanisms regulating SF-1 transcriptional activity by
comparing its genome-wide chromatin-binding sites in
conditions of basal and increased expression. Our results
allowed us to unexpectedly identify functional interactions
between SF-1 and Neuron-Restrictive Silencer Factor/
RE1-Silencing Transcription Factor (NRSF/REST), ori-
ginally described as a transcriptional repressor of neuronal
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differentiation genes in non-neural cells (15,16), in the
regulation of gene expression in adrenocortical cells.
MATERIALS AND METHODS
Cell culture
H295R/TR SF-1 cells (12) were cultured in Dulbecco’s
modified Eagle’s medium/F12 supplemented with penicil-
lin/streptomycin, 2% NuSerum (BD Biosciences), 1%
ITS+ (BD Biosciences), blasticidin (5mg/ml, Cayla
InvivoGen) and zeocin (100mg/ml, Cayla InvivoGen). As
a method of authentication, the cell karyotype and steroid
secretion profile were periodically tested. To induce SF-1
overexpression, cells were treated with doxycyline
(1 mg/ml, Sigma-Aldrich) for 3 days before being processed
for chromatin immunoprecipitation (ChIP). HeLa cells
were cultured in Dulbecco’s modified Eagle’s medium
(4.5 g/l glucose; Invitrogen) supplemented with penicillin-
streptomycin and 10% fetal calf serum (Invitrogen).
Gene knockdown and expression profiling
For knockdown experiments, H295R/TR SF-1 cells were
transfected with SF-1–specific (AGA GCC AGA GCU
GCA AGA UCG ACA A) (12), NRSF/REST–specific
(UAU CUU AAC AGG UUC CUU CUG GAC C) and
control (medium GC) Stealth siRNA (small interfering
RNA) oligos (Invitrogen) using the Amaxa nucleofection
technique (Lonza). Cells were electroporated with 80 pmol
siRNA/106 cells using solution R and the T-020 program
and then plated in 24-well plates. Total RNAwas extracted
72 h after nucleofection by the RNeasy Mini kit (Qiagen).
For SF-1 overexpression experiments, H295R/TR SF-1
cells were cultured in the presence or in the absence of
doxycycline for 3 days in 24-well plates before RNA ex-
traction. Total RNAwas used for gene expression profiling
on GeneChip HG-U133 Plus 2.0 (SF-1 overexpression ex-
periments) or HumanGene 1.0 ST (SF-1 andNRSF/REST
knockdown experiments) arrays (Affymetrix) using the
manufacturer’s protocols. Three biological replicates
were analyzed for both the knockdown and the
overexpression experiments. Data were analyzed using
the Affymetrix Command Console and Expression
Console softwares. Transcripts were considered as differ-
entially expressed when there was a 2-fold or greater dif-
ference in expression levels, with a P< 0.05. Differentially
expressed genes were assigned to different Gene Ontology
categories using the DAVID software (http://david.abcc.
ncifcrf.gov). The microarray data from this study have
been submitted to the NCBI Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo) under accession
number GSE43035.
ChIP
It was performed as previously described (17) with minor
modifications. Briefly, 108 H295R/TR SF-1 cells (pre-
treated or not with doxycycline for 3 days) were fixed
with 1% formaldehyde added to the culture medium for
10min at room temperature. After quenching with 0.25M
glycine, cells were washed with phosphate buffered saline
and sequentially with Lysis Buffer I [50mMHEPES–KOH
(pH 7.5), 140mMNaCl, 1mMEDTA, 10% glycerol, 0.5%
NP-40, 0.25% Triton X-100, containing protease inhibi-
tors], II [10mM Tris–HCl (pH 8.0), 200mM NaCl, 1mM
EDTA, 0.5mM EGTA, containing protease inhibitors]
and III [10mM Tris–HCl (pH 8.0), 100mM NaCl, 1mM
EDTA, 0.5mM EGTA, 0.1% Na-deoxycholate, 0.5% N-
lauroylsarcosine, supplemented with protease inhibitors]
and sonicated for 20 cycles at 20% amplitude with a
Branson sonifier to shear chromatin to a final average
size of 200 bp. After centrifugation to pellet debris, the
supernatant was incubated overnight at 4C on a rotating
wheel with anti SF-1 (#07-618 from Millipore or PP-
N1665-00 from R&D Systems) or anti NRSF/REST
(#07-579 from Millipore) antibodies adsorbed to
immunomagnetic protein A/protein G beads (Dynabeads,
Invitrogen). Beads carrying the immunoprecipitated chro-
matin were washed five times with RIPA buffer [50mM
HEPES–KOH (pH 7.5), 500mM LiCl, 1mM EDTA, 1%
NP-40, 0.7% Na-deoxycholate] and once with TE contain-
ing 50mM NaCl. DNA was eluted by incubation with
elution buffer [50mM Tris–HCl (pH 8.0), 10mM EDTA,
1% SDS] at 65C for 15min, and cross-linking reversal was
performed by incubation at 65C overnight. We systemat-
ically checked for successful immunoprecipitation of SF-1
in each sample (Supplementary Figure S1A). DNA was
then purified by RNAse A treatment and proteinase K
digestion, phenol-chloroform extracted, precipitated,
resuspended in 10mM Tris–HCl (pH 8.0) and quantified
on a Qubit fluorometer (Invitrogen).
High-throughput sequencing and data analysis
Immunoprecipitated DNA were sequenced on an Illumina
platform, and reads passing quality control criteria were
mapped to the human genome (version hg19) using
ELAND v2 software. SF-1-binding sites were identified
using the CisGenome v2 SeqPeak algorithm (18) from trip-
licate samples for each SF-1 dosage (basal or increased)
condition and input DNA as control, using the following
parameters: read extension length=150, local rate win-
dow=10kb, local rate cutoff=1e-005. The Sole-Search
web tool (19) was used to annotate the position of SF-1-
binding peaks in relationship to gene localization and to
import their sequence for further motif searching using the
MEME suite (20). The within-gene mode in the Sole-
Search Location Analysis Tool was used to assign
binding sites to genes. Overlaps between gene groups
were identified using the GeneVenn software (http://
genevenn.sourceforge.net). To calculate the significance
of overlap between gene sets, the chi-square test with
Yates’ correction was used, considering that 21 679 genes
were present in total on the HG-U133 Plus 2.0 arrays and
19 889 on the Human Gene 1.0 ST arrays. Formaldehyde-
Assisted Isolation of Regulatory Elements (FAIRE)
sequencing was performed as described (21). High-
throughput sequencing data are deposited in Gene
Expression Omnibus under accession number GSE44224.
Electrophoretic mobility shift assay
It was performed as previously described (12). The
sequence of probes used for electrophoretic mobility
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shift assay (EMSA) was as follows: SF-1-binding site
(mouse Mu¨llerian inhibiting substance promoter), CGTC
CCTCAAGGTCACCTTC; NRSF/REST binding site, C
TTCAGCACCACGGACAGCC; CRE (cAMP-response
element from rat somatostatin promoter), CTCCTTGG
CTGACGTCAGAGAGAGAG. Supershift was per-
formed using rabbit anti SF-1 polyclonal antibody (#07-
618, Millipore; 1 mg) or non-immune rabbit immuno-
globulin Gs (Sigma-Aldrich) at the same concentration
as a control.
Immunoprecipitation
The 3 107 H295R/TR SF-1 cells were resuspended in
800ml of buffer A [10mM HEPES–KOH (pH 7.5),
1.5mM MgCl2, 10mM KCl, 0.1mM EDTA, 0.2mM
EGTA, 0.2mM PMSF plus protease inhibitors] and
allowed to swell on ice for 15min. Then 25 ml of 20%NP-
40 were added, and cells were vortexed. After centrifuga-
tion, the pellet was resuspended in 300 ml of buffer C
[20mM HEPES–KOH (pH 7.5), 20% glycerol, 420mM
NaCl, 1.5mM MgCl2, 0.2mM EDTA, 0.2mM PMSF
plus protease inhibitors] and incubated for 30min on ice.
After centrifugation, the supernatant fraction was used for
coimmunoprecipitation after adjusting the salt concentra-
tion to 150mM. The supernatant was incubated with 3 mg
of preimmune rabbit immunoglobulin G (Abcam) or
antibodies directed against SF-1 (#07-618 from
Millipore) or NRSF/REST (#07-579 fromMillipore) over-
night at 4C on a rotating wheel. Twenty-five microliters of
Protein A magnetic beads (New England Biolabs) were
then added and incubated for 1 h at 4C. The antibody-
antigen-beads complex were washed four times with a
buffer containing 20mM HEPES–KOH (pH 7.5),
150mM NaCl, 0.5mM EDTA, 0.5% NP-40 and eluted
in Laemmli loading buffer at 70C. After denaturation at
100C for 5min, immunoblot analysis was performed using
the same antibodies used for immunoprecipitation.
Transient transfection
HeLa cells were transfected in 12-well plates using JetPEI
(Polyplus Transfection), according to the manufacturer’s
protocol. The NRSF/REST luc reporter harbors one
NRSF/REST binding site cloned in the KpnI-XhoI sites
of the pGL2 promoter vector. cDNAs encoding wild-
type, L451A/L452A (AF-2 mut) and G35E/R92Q (DBD
mut) SF1 were cloned in the HindIII-BamHI sites of the
pcDNA4/TO vector. Wild-type and mutant SF-1 proteins
were all expressed at similar levels in transfected HeLa cells
(Supplementary Figure S1B). A vector encoding Renilla
luciferase was cotransfected for normalization of transfec-
tion efficiency. Fourty-eight hours after transfection, cells
were lysed, and firefly/Renilla luciferase activities were
measured using the Dual Luciferase assay (Promega).
RESULTS
SF-1 dosage-dependent regulation of distinct categories
of genes in adrenocortical cancer cells
To identify the genes regulated by SF-1 in human
adrenocortical cancer cells, we performed knockdown
and overexpression experiments in the H295R/TR SF-1
cells, a subclone of the H295R cell line where SF-1
overexpression can be induced in a doxycycline-dependent
manner (12). Efficient SF-1 knockdown was obtained by
synthetic siRNA electroporation (Supplementary Figure
S1C). Eighty-three genes were upregulated and 125 genes
were downregulated by SF-1 siRNA compared with
cells transfected with control siRNA (Supplementary
Table S1). On the other hand, SF-1 overexpression
(Supplementary Figure S1C) produced upregulation of
184 genes and downregulation of 91 genes in H295R
cells (Supplementary Table S1). Remarkably, the
categories of genes whose expression was affected by SF-
1 knockdown and genes regulated by SF-1 overexpression
only marginally overlap. Genes negatively regulated by
SF-1 knockdown (activated by SF-1) are enriched in
genes involved in lipid and steroid metabolism, Ras
guanyl-nucleotide exchange factor activity and cytoskel-
eton function, whereas genes positively regulated by SF-
1 knockdown (repressed by SF-1) are enriched in genes
involved in angiogenesis, cell proliferation and apoptosis,
interaction with the extracellular matrix, Notch and
TGFb signaling (Table 1; full lists of enriched Gene
Ontology categories for genes regulated by SF-1
knockdown are shown in Supplementary Table S2).
Conversely, genes repressed by SF-1 overexpression are
enriched in genes involved in cell adhesion, angiogenesis,
ion transport and apoptosis, whereas genes positively
regulated by SF-1 overexpression are enriched in genes
involved in angiogenesis, lipid and steroid metabolism,
ion transport (Table 1; full lists of enriched Gene
Ontology categories for genes regulated by SF-1
overexpression are shown in Supplementary Table S2).
Comparison of genes regulated (both up- and down-) by
SF-1 knockdown and overexpression revealed that only a
small subset was common among the different experimen-
tal conditions (Figure 1). Only three genes can be con-
sidered SF-1 ‘fully’ positive targets, as they are
downregulated by SF-1 knockdown and upregulated by
SF-1 overexpression. Conversely, 11 other genes are SF-
1 ‘fully’ negative targets, as their expression is upregulated
by SF-1 knockdown and downregulated by SF-1
overexpression. It is interesting to notice that the expres-
sion of some SF-1 target genes follows a coordinately
regulated bell-shaped pattern according to factor dosage,
with one group being downregulated and the other being
upregulated both by SF-1 knockdown and overexpression
(Supplementary Table S3). Altogether, these findings
show that distinct categories of genes are regulated ac-
cording to SF-1 dosage in H295R cells.
The localization of SF-1 genomic-binding sites differs in
conditions of basal and increased dosage and is correlated
with changes in gene expression
To understand the bases for differential gene regulation by
varying SF-1 dosage, we identified genome-wide binding
sites of SF-1 to chromatin of H295R cells in conditions of
basal expression and overexpression (Figure 2). In tripli-
cate experiments, SF-1 bound to 4393 sites in basal ex-
pression conditions, whereas it bound to 11 910 sites when
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overexpressed. The majority (83.5%) of SF-1-binding sites
in basal conditions was located distal (>10 kb) to gene
boundaries, whereas when SF-1 was overexpressed, its as-
sociation to gene-proximal sites (<10 kb) increased
(30.5%) (Figure 2A and Supplementary Figure S2A and
B). In particular, the percentage of SF-1-binding sites in
close proximity of transcription start sites (1000
to+1000 bp) was increased more than 3-fold when SF-1
was overexpressed. In basal expression conditions, the per-
centage of SF-1-binding sites lying in gene deserts (distant
>100 kb from gene boundaries) totaled 40.6%, whereas it
was reduced to 26.4% when SF-1 was overexpressed
(Supplementary Figure S2C). Remarkably, only 545
SF-1-binding sites were common to the basal and
overexpression conditions (Supplementary Table S4).
However, the overlap between genes in whose proximity
SF-1 bound in both conditions was more important: when
considering SF-1 binding within <100 kb of transcription
start sites, it bound in the proximity of 2638 unique genes
in basal expression conditions, whereas this number
increased to 6248 when SF-1 was overexpressed. In all,
1497 genes were common between these two data sets
(Figure 2B and Supplementary Table S4). We next
examined the relationship between genes in whose prox-
imity SF-1 bound in basal and overexpression conditions
and genes that are differentially regulated by SF-1 dosage
(Figure 3). No significant overlap existed between genes in
whose proximity SF-1 bound only in conditions of basal
expression and genes that were upregulated following SF-
1 overexpression in H295R cells (P= 0.91). Conversely, a
Figure 1. Comparison of genes regulated positively and negatively by SF-1 knockdown and overexpression in H295R cells. Blue circles denote genes
downregulated by SF-1 knockdown. Red circles denote genes upregulated by SF-1 overexpression. Orange circles denote genes upregulated by SF-1
knockdown. Green circles denote genes downregulated by SF-1 overexpression. The number of common genes is indicated in the intersection
between circles. SF-1 ‘fully’ positive and negative target genes are downregulated by SF-1 knockdown/upregulated by its overexpression and
upregulated by SF-1 knockdown/downregulated by its overexpression, respectively. The expression of some SF-1 target genes follows a bell-
shaped pattern according to dosage of the factor (curves at the bottom of the figure).
Table 1. Gene categories modulated by SF-1 knockdown and overexpression in H295R cells
Downregulated by
SF-1 knockdown
Upregulated by SF-1 knockdown Downregulated by
SF-1 overexpression
Upregulated by
SF-1 overexpression
Lipid and steroid metabolism Angiogenesis Angiogenesis Angiogenesis
Ras guanyl-nucleotide exchange factor
activity
Cell prolifetration Apoptosis Lipid and steroid metabolism
Cytoskeleton function Apoptosis Cell adhesion Ion transport
Interaction with the extracellular matrix Ion transport
Notch signaling
TGFb signaling
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significant association existed (P=0.0006) between genes
in whose proximity SF-1 bound both in basal and
overexpression conditions and genes upregulated follow-
ing SF-1 overexpression. The highest significant associ-
ation (P< 0.0001) was between genes in whose proximity
SF-1 bound only when overexpressed and genes
upregulated following its overexpression. When
considering genes downregulated following SF-1
overexpression, a significant association existed with
genes in whose proximity SF-1 bound only in basal ex-
pression conditions (P= 0.0016), and with genes
commonly bound both by basal and overexpressed SF-1
(P= 0.0007), whereas no significant association existed
with genes in whose proximity SF-1 bound only in
Figure 3. Correlation between SF-1 binding and gene regulation. Green circles denote genes downregulated by SF-1 overexpression. Red circles
denote genes upregulated by SF-1 overexpression. Yellow circles denote genes bound by SF-1 only in basal expression conditions. Blue circles denote
genes bound by SF-1 only when overexpressed. Pale blue circles denote genes bound by SF-1 both in basal and overexpression conditions. The
number of common genes is indicated in the intersection between circles. The significance value for each association is indicated (chi-square with
Yates’ correction test).
Figure 2. Relationship of SF-1-binding sites to the localization of genes in H295R cells in basal and overexpression conditions. (A) Pie charts
showing the distribution of SF-1-binding sites in relationship to transcription start sites in basal (left) and increased (right) factor expression
conditions. Legend indicates distance from transcription start sites in base pairs. The percentage of SF-1-binding sites in each distance group is
indicated. (B) Overlap between genes in whose proximity (100 kb) SF-1-binding sites were detected. Yellow circle denotes basal SF-1 dosage. Blue
circle denotes increased SF-1 dosage.
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overexpression conditions (P= 0.53). Altogether, these
data show that differential SF-1 binding at basal and
increased expression levels has a significant impact on
gene expression in H295R cells.
A subset of SF-1-binding sites colocalizes with newly
accessible sites in H295R cells chromatin
To investigate the relationship of SF-1-binding sites with
accessible sites in chromatin, we used FAIRE-seq. Using
this technique, nucleosome-depleted DNA sequences are
preferentially identified that overlap with regulatory sites
in the genome (22). In H295R cells expressing basal levels
of SF-1, 34 421 FAIRE sites were identified, while 31 217
were present in cells overexpressing SF-1, with 18 703
FAIRE sites being common between both conditions.
These data show that FAIRE sites undergo substantial
rearrangements after SF-1 overexpression in H295R
cells. FAIRE sites were preferentially localized inside or
in the proximity of genes, both in SF-1 basal expression
and overexpression conditions (Supplementary Table S4).
Remarkably, 1008 SF-1-binding sites identified in SF-1
overexpression conditions overlapped with FAIRE sites
present only when SF-1 was overexpressed. This indicates
that SF-1 is able to associate with newly accessible sites in
H295R cells chromatin on its overexpression and may
have a role in their establishment.
Enrichment of specific DNA sequences in SF-1-binding
sites in H295R cells
Sequence enrichment analysis of SF-1-binding sites using
several algorithms (20) revealed that the consensus SF-1-
binding sequence identified in vitro (23) or close variants of
it are significantly enriched in SF-1-binding sites in the
chromatin of H295R cells both when the factor is ex-
pressed at basal levels and in overexpression conditions
(Figure 4A). Unexpectedly, a sequence matching the
consensus binding sequence for transcription factor
NRSF/REST (24) was also significantly enriched in SF-
1-binding sites in both basal and high SF-1 dosage condi-
tions (Figure 4B). Importantly, the presence of SF-1 and
NRSF/REST consensus-binding sites in sequences bound
by SF-1 nearly always appears mutually exclusive, as only
minimal overlap existed between SF-1-binding sites con-
taining the SF-1 consensus sequence and those containing
the NRSF/REST consensus sequence (1.2% for basal SF-
1 dosage and 1% for increased SF-1 dosage).
FAIRE sites in H295R cells were significantly enriched
in sequences matching a variety of transcription factors
binding sites, including the SF-1 sequence at a high sig-
nificance level (P= 7.3e-300 in basal SF-1 expression con-
ditions and P= 1.7e-433 when SF-1 was overexpressed)
(Supplementary Figure S3). CTCF sites were also fre-
quently represented in FAIRE sites (P= 4.8e-261 in
basal SF-1 expression conditions and P= 1.8e-60 when
SF-1 was overexpressed) consistently with previous
reports in other cell lines (22). Remarkably, sequences in
SF-1-binding sites in overexpression conditions
overlapping with FAIRE sites present only when SF-1
was overexpressed were significantly enriched in SF-1
(P= 1.7e-07) and NRSF/REST (P= 2.9e-09) but not
CTCF (P= ns) sites.
A dynamic interplay between SF-1 and NRSF/REST in
the regulation of gene expression
The unexpected enrichment of NRSF/REST binding se-
quences in SF-1-binding sites prompted us to analyze the
functional interactions between those factors in the regu-
lation of gene expression in H295R cells. Importantly,
NRSF/REST sites were also significantly enriched in SF-
1-binding sites identified using a different anti SF-1
antibody for ChIP (P= 8.4e-08). We mapped the distri-
bution of NRSF/REST binding sites in H295R cells by
Figure 4. Enrichment of SF-1 and NRSF/REST binding sequences in SF-1-binding sites in H295R cells. (A), A motif closely matching the sequence
to which SF-1 binds in vitro is significantly enriched in SF-1-binding sites, both at basal (left) and increased (right) SF-1 dosage. (B), A motif (top)
closely matching the NRSF/REST binding sequence is significantly enriched in SF-1-binding sites.
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ChIP-seq. NRSF/REST bound to a similar number of
sites in conditions of basal (5322 sites) and increased
(5058 sites) SF-1 expression, respectively. Although sub-
stantial redistribution of NRSF/REST binding sites
occurred on increase of SF-1 dosage, with 3471 binding
sites overlapping in conditions of basal and increased SF-1
dosage, their localization in relationship to gene positions
only underwent minimal changes, with the majority of
sites being intragenic (39.4% both under basal and
increased SF-1 dosage; Supplementary Figure S4).
Sequence enrichment analysis found the consensus
NRSF/REST binding sequence as highly enriched both
in conditions of basal (P= 7.5e-306) and increased
(P= 1.2e-300) SF-1 expression, while no sequence
related to the SF-1 consensus-binding site was detected
as significantly enriched. Remarkably, 109 (2% of total
NRSF/REST binding sites; 2.5% of total SF-1-binding
sites) and 196 (3.8% of total NRSF/REST binding sites;
1.6% of total SF-1-binding sites) NRSF/REST and SF-
1-binding sites overlapped in conditions of basal and
increased SF-1 expression, respectively. Motif searching
in those binding sites identified the NRSF/REST consen-
sus sequence in 105 of 109 cases (96.3%; basal SF-1
dosage) and 150 of 196 cases (76.5%; increased SF-1
dosage), whereas the SF-1 consensus sequence was
present in only 19 of 109 cases (17.4%; basal SF-1
dosage) and 30 of 196 cases (15.3%; increased SF-1
dosage), respectively. These differences are extremely sig-
nificant (P< 0.0001 in both cases, Fisher’s exact test) and
strongly suggest that the presence of NRSF/REST, but
not SF-1, consensus sequences is preferentially required
for interaction of SF-1 with the genomic-binding sites
that it shares with NRSF/REST in H295R cells.
Consistent with this hypothesis, when binding of H295R
nuclear extracts to a NRSF/REST sequence was assayed
in an EMSA, an intermediate mobility complex formed,
which co-migrated with the complex formed on the SF-1
consensus-binding sequence (Figure 5A). This complex
was supershifted by an antibody specifically recognizing
SF-1, whereas non-immune rabbit immunoglobulin
Gs had no effect on the mobility of the complex.
Moreover, the anti–SF-1 supershifted complex was
competed both by cold NRSF/REST and SF-1 sequences
but not by an unrelated (cAMP-response element, CRE)
cold sequence. Conversely, the complex did not form
on the CRE sequence. Those SF-1-containing complexes
Figure 5. Interaction of SF-1 with NRSF/REST. (A) EMSA showing interaction of SF-1 with the NRSF/REST sequence. Lane 1, free NRSF/REST
labeled probe; lanes 2–7, binding of H295R nuclear extracts to the NRSF/REST labeled probe; lanes 8–13, binding of H295R nuclear extracts to the
CRE labeled probe; lanes 14–15, binding of H295R nuclear extracts to the labeled SF-1 probe. In lanes 3, 9 and 14, rabbit immunoglobulin G was
added, and in lanes 4–7, 10–13 and 15, the anti SF-1 antibody was added to the binding reaction, respectively. Cold NRSF/REST, SF-1 and CRE
probes were also added to binding reactions in lanes 5 and 11, 6 and 12, 7 and 13, respectively. An intermediate mobility complex (arrowhead) was
formed, which comigrates with the complex formed by the same extracts on the SF-1 consensus binding sequence (lane 14). This complex was
supershifted (asterisk) by an anti SF-1 antibody (lane 4), but not by non-immune rabbit immunoglobulin Gs (lane 3). The complex did not form on
an unrelated DNA sequence (CRE, lanes 8–12). An overexposed image of the same EMSA experiment is shown in Supplementary Figure S5.
(B) SF-1 can be co-immunoprecipitated with NRSF/REST from H295R nuclear extracts. Immunoprecipitates were analyzed by immunoblotting for
the presence of SF-1 and NRSF/REST. Input, 1:10 input extract; IgG, rabbit immunoglobulin G; aSF-1, anti SF-1 antibody; aNRSF/REST, anti
NRSF/REST antibody. The asterisk indicates a non-specific band present in the SF-1 immunoblotting.
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are more evident in an overexposed image of the same
EMSA experiment shown in Supplementary Figure S5.
Furthermore, SF-1 and NRSF/REST could be co-
immunoprecipitated from H295R nuclear extracts
(Figure 5B).
Based on these results, we examined whether a func-
tional interaction exists between SF-1 and NRSF/REST
in the regulation of gene expression. As shown before (25),
in non-neuronal cells (HeLa), the NRSF/REST binding
sequence confers significant transcriptional repression
activity when cloned upstream a basal promoter (NRSF/
REST luc; Figure 6A). Wild-type SF-1 could significantly
relieve transcriptional repression of NRSF/REST luc,
whereas both an AF-2 (L451A/L452A) (12) and a DNA-
binding domain (G35E/R92Q) (26) SF-1 mutants were
inactive (Figure 6B). These data show that SF-1 transcrip-
tional activity, either directly or interfering with repression
by NRSF/REST, and DNA-binding properties are both
required to relieve transcriptional repression imparted by
NRSF/REST. We then looked at the impact of varying
SF-1 dosage on NRSF/REST-regulated gene expression in
H295R cells. In this cell line, as assessed by knockdown
experiments (Supplementary Figure S1D), NRSF/REST
regulated negatively the expression of 28 genes and posi-
tively the expression of 4 genes in basal SF-1 expression
conditions (Supplementary Table S5). NRSF/REST tar-
get genes were enriched in genes involved in ion
trafficking, membrane function and, surprisingly, also in
steroidogenesis (Supplementary Table S5). It is important
to notice that SF-1 and NRSF/REST share a highly sig-
nificantly overlapping (P< 0.0001, Fisher’s exact test)
subset of target genes, including the steroidogenic genes
CYP21A2 and CYP19A1 (Figure 6C and Supplementary
Table S5). Strikingly, when SF-1 was overexpressed,
an overlap of 18 genes negatively regulated by
NRSF/REST existed with genes negatively regulated by
this factor in the presence of a basal SF-1 dosage, while 10
were specific only to the basal SF-1 dosage and 10 to the
overexpressed SF-1 condition (Figure 6D and
Supplementary Table S5). In particular, NRSF/REST re-
pression of CYP21A2 and CYP19A1 was abrogated by an
increased SF-1 dosage. Moreover, the NRSF/REST
positive regulatory action was completely impaired by
overexpressed SF-1 (Figure 6D).
DISCUSSION
For several transcription factors, gene dosage is a critical
determinant of their biological function, a paradigm case
being represented by Oct-3/4 dosage in mouse embryonic
stem cells (27). Among nuclear receptors, the role of
androgen receptor and estrogen receptor-a amplification
and overexpression in prostate and breast cancer progres-
sion, respectively, is well known (28,29). The first indica-
tions about the importance of SF-1 dosage for its
biological function came from genetic inactivation experi-
ments in mice. Although Nr5a1 homozygote inactivation
causes complete absence of adrenal glands and gonads
and spleen defects (4,5,30), Nr5a1 heterozygote mice
have hypoplastic adrenals and gonads, in the presence of
decreased corticosterone and increased (especially after
stress) ACTH plasma levels (8), also displaying a deficient
compensatory adrenal growth following unilateral
adrenalectomy (9). It is particularly remarkable that
Figure 6. Modulation of NRSF/REST-dependent gene expression by SF-1 dosage. (A) The NRSF/REST binding sequence cloned upstream of a
basal promoter represses its expression in HeLa cells. **P= 0.0025, Wilcoxon signed rank test. (B) Co-transfection of wild-type, but not AF-2
(L451A/L452A; AF-2 mut) and DNA-binding domain (G35E/R92Q; DBD mut) SF-1 mutants relieved transcriptional repression imparted by the
NRSF/REST sequence. *P< 0.05, ANOVA with Dunnett’s multiple comparison test. (C) Comparison of the sets of genes downregulated by SF-1
knockdown (positively regulated by SF-1) and upregulated by NRSF/REST knockdown (negatively regulated by NRSF/REST). (D) Comparison of
NRSF/REST-regulated genes in H295R cells in conditions of basal and increased SF-1 dosage. Blue circles denote genes regulated by NRSF/REST
in the presence of basal SF-1 dosage; red circles denote genes regulated by NRSF/REST in the presence of increased SF-1 dosage. The number of
common genes is indicated in the intersection between circles.
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different tissues appear to possess different thresholds of
sensitivity to Nr5a1 gene dosage, as shown by the finding
that SF-1 re-expression in the Nr5a1 null background
rescued gonadal and spleen defects, but failed to rescue
adrenal development (31). This different sensitivity to
NR5A1 dosage also exists in humans, where heterozygote
NR5A1 mutations are most commonly associated with
gonadal, but not adrenal, defects (10,11). Conversely,
SF-1 overexpression is associated with increased
adrenocortical tumor cell proliferation, development of
adrenocortical tumors in mice and is a widespread
finding in pediatric adrenocortical tumors, whereas it
confers a more severe prognosis to adult adrenocortical
cancers (12–14). Consistent with the relevant phenotypic
effects of different SF-1 dosages, our work shows that
different SF-1 levels in the H295R adrenocortical tumor
cell line differentially regulate the expression of numerous
genes, which are involved in a variety of biological
processes [reviewed in (32)]. Remarkably, the functions
of genes regulated by different SF-1 dosages only partially
overlap, with mainly distinct gene categories being
regulated by basal and overexpressed SF-1 levels
(Table 1). SF-1 target genes are implicated in functions
as diverse as ion transport, lipid metabolism, angiogenesis,
cell survival and control pivotal pathways such as TGFb
and Notch signaling. As a consequence, only a limited set
of genes is commonly regulated by SF-1 both in basal and
overexpression conditions. These data significantly extend
the list of SF-1 targets identified by previous studies in
H295R cells (33–35) and suggest that fine regulation of
SF-1 dosage is a critical determinant of its action during
adrenal development, function and tumorigenesis. It is
also interesting to notice that the expression of some SF-
1 target genes follows a bell-shaped pattern according to
factor dosage, with one group being downregulated and
the other being upregulated both by SF-1 knockdown and
overexpression (Supplementary Table S3). NOV, encoding
a secreted pro-apoptotic factor for adrenocortical cancer
cells (36), is an example of those genes that are tightly
regulated according to SF-1 dosage.
To better understand the bases of the peculiar mode of
gene expression regulation by SF-1, we identified its chro-
matin-binding sites on a genome-wide scale using ChIP-
seq both in basal and in overexpression conditions. Under
basal expression conditions, SF-1 bound to >4000 sites in
H295R cells, which nearly tripled when SF-1 was
overexpressed. Similarly to many other nuclear receptors
(37), the majority of SF-1 binding sites was in both cases
localized distal to genes. However, when SF-1 was
overexpressed, its association to gene-proximal sites
markedly increased (30.5 versus 16.6% in basal expression
conditions). It is interesting to notice that the percentage
of genes commonly bound by SF-1 in basal and
overexpressed conditions exceeded the number of
common binding sites, suggesting that SF-1-regulated
genes have alternative SF-1-binding sites. Our data show
that at least part of the regulation operated by SF-1 on its
target genes can be explained by differential SF-1 binding
at basal or increased expression levels. Particularly, a high
correlation existed between the localization of SF-1-
binding sites present only when the factor was
overexpressed and genes upregulated selectively in that
condition, consistently with the classical SF-1 function
as a transcriptional activator. Similarly, the correlation
between downregulation of certain genes when SF-1 was
overexpressed in the absence of SF-1 binding, which was
present only in conditions of basal factor dosage, can be
interpreted as a withdrawal of transcriptional activation.
On the other hand, it is interesting to notice that a correl-
ation also existed between downregulation of a subset of
genes and SF-1 binding in their proximity in both basal
and overexpression conditions. This suggests that in
certain cases, SF-1 may directly repress gene expression,
consistently with previous reports (38,39) and findings for
other nuclear receptors classically considered as pure tran-
scriptional activators (40). Finally, indirect mechanisms
(e.g. through regulation of the expression of other tran-
scription factors) or long-range effects are likely to
account for the regulatory function of different SF-1
dosages on genes in whose proximity the factor does not
directly bind.
We also studied the relationship of SF-1-binding sites
with accessible sites in chromatin, identified by FAIRE-
seq (22), which are the hallmark of regulatory regions in
the genome. In H295R cells, FAIRE sites are remarkably
highly enriched for a sequence highly similar to the
sequence bound by SF-1 in vitro (23), together with
other transcription factor (including CTCF, known to
bind to insulator regions) binding sites. This is consistent
with results from the ENCODE consortium showing that
cell-type selective open chromatin regions harbor DNA
sequence motifs bound by master regulators of cellular
identity (22). The sequence bound by SF-1 in living cells
matches almost completely the consensus sequence defined
in vitro. However, no enrichment is present for a pyrimi-
dine lying just 50 to the cytosine upstream the nuclear
receptor half-site, which makes crucial contacts with the
C-terminal extension A box in the structures of SF-1 and
its close homologue LRH-1 DBDs complexed with their
bound sequences (41,42). These data suggest that SF-
1-cognate DNA interaction is probably stabilized in vivo
by interaction with the chromatin context or with other
transcriptional complexes. It is also remarkable that SF-1
overexpression in H295R cells induced substantial modi-
fications in the localization of their FAIRE sites. In par-
ticular, a subset of SF-1 binding sites was co-localized with
FAIRE sites only present when SF-1 was overexpressed.
This suggests that SF-1 may be associated with chromatin-
remodeling complexes and actively participate in forma-
tion of accessible sites in chromatin, similarly to other
nuclear receptors (43).
An unexpected result of our study is represented by the
discovery of a functional interaction of SF-1 with the tran-
scription factor NRSF/REST in regulating gene expres-
sion in adrenocortical cancer cells. NRSF/REST was
identified as a transcriptional repressor that suppresses
expression of neural genes in non-neuronal cells (15,16)
and is believed to have a fundamental role to restrict
neural gene expression to the nervous system. However,
recent studies have suggested a broader role for this
protein in fine-tuning neural gene expression, rather
than as a regulator of neurogenesis or cell fate (44).
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NRSF/REST represses transcription by binding an
extended DNA recognition sequence (24,45) and recruit-
ing a corepressor complex (25). Little is known about the
role of NRSF/REST beyond its role in restricting neural
identity. Remarkably, a RNAi-based genetic screen
identified a role for NRSF/REST as a tumor suppressor
(46). In adrenocortical H295R cells, a previous report
described a role for NRSF/REST in the regulation of al-
dosterone and cortisol production by regulating CYP11B1
and CYP11B2 expression through repression of the
CACNA1H gene (47).
Here, we have shown that SF-1 and NRSF/REST func-
tionally interact in regulating gene expression in H295R
adrenocortical cancer cells. The NRSF/REST binding
sequence was significantly enriched in SF-1-binding sites
in H295R cells chromatin, both in basal and increased
SF-1 expression conditions. Importantly, enrichment of
the NRSF/REST sequence was confirmed in SF-
1-binding sites also by ChIP with a different anti-SF-1
antibody. Moreover, that sequence was also enriched in
FAIRE sites present only when SF-1 was overexpressed.
Mapping of NRSF/REST binding sites in H295R cells by
ChIP-seq showed that a small percentage of them
overlapped with SF-1-binding sites, both under basal and
increased SF-1 expression conditions. SF-1 and NRSF/
REST could be co-immunorecipitated from H295R
nuclear extracts and among the complexes formed by
H295R nuclear extracts with the NRSF/REST sequence
in EMSA, an intermediate mobility complex was detectable
which contained SF-1, as shown by supershift with an anti-
SF-1 antibody, and comigrated with the complex formed
by SF-1 on its consensus binding sequence. In the over-
whelming majority of cases, SF-1-binding sites mapped
by ChIP-seq containing the NRSF/REST sequence did
not include a consensus SF-1-binding sequence.
Moreover, the NRSF/REST sequence was significantly
more enriched than the SF-1 consensus sequence in the
binding sites commonly occupied by NRSF/REST and
SF-1. Altogether, these findings strongly argue in favor of
the possibility for SF-1 to bind to some genomic sites in
H295R cells by interacting with the NRSF/REST
sequence. This binding is probably stabilized by interaction
of SF-1 with the NRSF/REST protein bound to its cognate
sequence, as suggested by the fact that the two proteins can
be co-immunoprecipitated. Functional experiments are
supporting this scenario, as cotransfection of wild-type,
but not AF-2 mutant or DBD mutant, SF-1 could relieve
repression imparted by the NRSF/REST sequence on a
basal promoter.
Knockdown experiments showed that NRSF/REST
regulates a small set of genes in H295R cells, both nega-
tively and positively [these latter ones probably through
indirect effects; see (45)]. Apart from classical target genes
expressed in neuronal cells (ion channels, adhesion mol-
ecules) and in H295R cells, NRSF/REST also regulated
genes involved in steroidogenesis. SF-1 and NRSF/REST
shared a significant proportion of their target genes and
SF-1 overexpression reshaped the repertoire of NRSF/
REST-regulated genes, which only partially overlapped
in conditions of basal and increased SF-1 dosage. SF-1
overexpression completely inhibited the positive effect
of NRSF/REST on a subset of genes and relieved repres-
sion of CYP21A2 and CYP19A1, two important
steroidogenic genes. These data show that NRSF/REST
has a novel function in regulating the steroidogenic
program in adrenocortical cells and, together with recent
reports in other systems (48–50), suggest that it may have
a broad role in regulating tissue-specific gene expression
programs.
In conclusion, we have shown here that SF-1 regulates
distinct categories of genes in adrenocortical cancer cells
according to its dosage and that binding of the factor to
chromatin sites in conditions of different SF-1 dosage cor-
relates with differential regulation of gene expression.
Furthermore, these studies allowed us to discover an un-
expected functional interaction of SF-1 with NRSF/REST
in regulating steroidogenic gene expression. These data are
important to understand the mechanisms of gene expres-
sion regulation by altered SF-1 dosages in development
and cancer and to develop new therapeutic tools targeting
SF-1 and its target genes.
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